DexCom Inc (DXCM) stock
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3030% below fair value
$83.33+1.94 (+2.38%)
Close on Nov 13, 2026Market cap $31.08BP/E 32.8Yield –
DexCom EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
DexCom's EPS for the twelve months ending Sep 30, 2026 was $2.54, up 41.9% year over year. For fiscal 2025 it was $2.09, up 47.2% from the year before. The highest annual figure on record is $2.09 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.09 | +47.2% |
| FY2024 | Dec 31, 2024 | $1.42 | +9.2% |
| FY2023 | Dec 31, 2023 | $1.30 | +58.5% |
| FY2022 | Dec 31, 2022 | $0.82 | +54.7% |
| FY2021 | Dec 31, 2021 | $0.53 | -60.2% |
| FY2020 | Dec 31, 2020 | $1.33 | +383.6% |
| FY2019 | Dec 31, 2019 | $0.28 | – |
| FY2018 | Dec 31, 2018 | -$0.36 | – |
| FY2017 | Dec 31, 2017 | -$0.14 | – |
| FY2016 | Dec 31, 2016 | -$0.20 | – |
| FY2015 | Dec 31, 2015 | -$0.18 | – |
| FY2014 | Dec 31, 2014 | -$0.07 | – |
| FY2013 | Dec 31, 2013 | -$0.10 | – |
| FY2012 | Dec 31, 2012 | -$0.20 | – |
| FY2011 | Dec 31, 2011 | -$0.17 | – |
| FY2010 | Dec 31, 2010 | -$0.24 | – |
| FY2009 | Dec 31, 2009 | -$0.30 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.72 | +2.9% |
| Q2 FY2026 | Jun 30, 2026 | $0.64 | +42.2% |
| Q1 FY2026 | Mar 31, 2026 | $0.51 | +88.9% |
| Q4 FY2025 | Dec 31, 2025 | $0.67 | +81.1% |
| Q3 FY2025 | Sep 30, 2025 | $0.70 | +105.9% |
| Q2 FY2025 | Jun 30, 2025 | $0.45 | +28.6% |
| Q1 FY2025 | Mar 31, 2025 | $0.27 | -25.0% |
| Q4 FY2024 | Dec 31, 2024 | $0.37 | -39.3% |
| Q3 FY2024 | Sep 30, 2024 | $0.34 | +17.2% |
| Q2 FY2024 | Jun 30, 2024 | $0.35 | +25.0% |
| Q1 FY2024 | Mar 31, 2024 | $0.36 | +200.0% |
| Q4 FY2023 | Dec 31, 2023 | $0.61 | +177.3% |
| Q3 FY2023 | Sep 30, 2023 | $0.29 | +20.8% |
| Q2 FY2023 | Jun 30, 2023 | $0.28 | +133.3% |
| Q1 FY2023 | Mar 31, 2023 | $0.12 | -47.8% |
| Q4 FY2022 | Dec 31, 2022 | $0.22 | – |
| Q3 FY2022 | Sep 30, 2022 | $0.24 | +14.3% |
| Q2 FY2022 | Jun 30, 2022 | $0.12 | -36.8% |
| Q1 FY2022 | Mar 31, 2022 | $0.23 | +64.3% |
| Q4 FY2021 | Dec 31, 2021 | -$0.01 | -101.3% |
| Q3 FY2021 | Sep 30, 2021 | $0.21 | +15.1% |
| Q2 FY2021 | Jun 30, 2021 | $0.19 | +58.3% |
| Q1 FY2021 | Mar 31, 2021 | $0.14 | +166.7% |
| Q4 FY2020 | Dec 31, 2020 | $0.79 | +216.0% |
| Q3 FY2020 | Sep 30, 2020 | $0.18 | +46.0% |
| Q2 FY2020 | Jun 30, 2020 | $0.12 | – |
| Q1 FY2020 | Mar 31, 2020 | $0.05 | – |
| Q4 FY2019 | Dec 31, 2019 | $0.25 | – |
| Q3 FY2019 | Sep 30, 2019 | $0.13 | -3.8% |
| Q2 FY2019 | Jun 30, 2019 | -$0.03 | -135.3% |
| Q1 FY2019 | Mar 31, 2019 | -$0.07 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.51 | – |
| Q3 FY2018 | Sep 30, 2018 | $0.13 | – |
| Q2 FY2018 | Jun 30, 2018 | $0.09 | +1033.3% |
| Q1 FY2018 | Mar 31, 2018 | -$0.07 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.03 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.01 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.01 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.12 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.02 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?